Drinking to
Remember
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Is Wine Good for Your Brain?
By Ethan Bradley
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lzheimer’s runs in my
family. My grandma has
it; her mother had it.
It’s a sad reality for us. We began
to understand what it was going
to look like for my grandma when
she started to forget things that
she never used to. There’s no one
more organized than my grandma;
growing up, her family calendar is
what kept that side of the family
on top of all of the sports games,
birthdays, and religious events
that the grandkids were involved
with. When her Alzheimer’s started
setting in, my grandparents’
house was filled with post-it notes
scribbled with reminders of things
that are usually easy to remember.
It’s not so strange to see “Call soand-so” on the fridge or “Clean”
on the dishwasher, but when she
had to start writing reminders to
take her pills at breakfast or other
tasks that she had successfully
accomplished without reminders
for years, we knew something was
up. Today, she doesn’t know if I am
still in college, what day, month or
year it is, or if she ate breakfast. It
doesn’t make her any less lovely
to be around: we still enjoy our
trips for Starbucks or Dairy Queen
milkshakes. I don’t think she could
be any happier, I just wish her
brain would cooperate with her
livelihood.
One thing my grandma loves
to do is drink wine. This isn’t new,
but her Alzheimer’s has definitely
given her the ability to live in the
moment. And at any given time,
she may just want some more
wine. As it turns out, wine has
clear health benefits. Recently, our
family has been wondering if the
wine does anything to help her
brain, given that it’s deteriorating
due to her disease. Could there
be a connection between her
disease progression and wine
consumption? We cannot know
simply from Grandma Becky,
but scientists have done a hefty
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amount of research surrounding
the health benefits of wine, and
the results have implications for
both people with Alzheimer’s like
my grandmother and the general
public of aging individuals.

Alzheimer’s Disease
and Aging
Alzheimer’s disease currently
affects 5.8 million Americans
(alz.org). The disease is a type
of dementia that causes people
to have memory issues, altered
behavior, and difficulty thinking.
Symptoms of the disease arise
and progress slowly, but eventually
people with Alzheimer’s can have
a difficult time with daily tasks and
can lose important memories, like
the names of close family members.
Alzheimer’s disease is the cause of
60-80% of dementia cases, so not
all dementia is due to Alzheimer’s.
Dementia due to Alzheimer’s has
tell-tale signs such as buildup of
harmful proteins that clog and
deteriorate the brain.
Alzheimer’s is separate from
the normal aging process. Older
people have the highest likelihood
of
developing
the
disease,
but Alzheimer’s disease has
complications that do not occur in
the typical process of aging. People
younger than 65 may develop
early-onset Alzheimer’s, which is a
form of the disease that begins at
a younger age and progresses at a
steady rate. In the early stages of
the disease, behavior is only slightly
altered and dementia is mild.
However, in the later stages, most
people with Alzheimer’s lose their
ability to continue conversations,
may hallucinate, and have seizures.
Contrary to popular belief, people
die from Alzheimer’s rather than
with the disease. Death tends to
occur 8.5 years after diagnosis, but
that number varies greatly from
person to person1.
Changes in the physical brain

happen long before any behavioral
changes occur in Alzheimer’s
disease. These brain alterations can
be observed, sampled, and used
for diagnoses. A brain is made up
of many different regions that are
responsible for specific actions.
Just like there are regions specific
for interpreting visual and auditory
information from the eyes and ears,
there are brain regions responsible
for memory and emotions. It is only
after these regions are damaged
due to Alzheimer’s that memory
is impaired. One region known
for its importance of committing
short term memories to long term
memory is the hippocampus.
Oftentimes, scientists choose to test
the function of the hippocampus
in studies that assess memory.
The hippocampus, like all of the
other brain regions, is made up of
cells called neurons, which are the
microscopic cellular building blocks
that are responsible for signaling in
the brain.
Diseases that impact cognition,
like Alzheimer’s, prevent neurons
from functioning how they should.
Alzheimer’s disease is characterized
by the buildup of two harmful
proteins in the regions of the brain
that are important for memory and
cognition. The first of these two
proteins, amyloid beta, builds up
in the spaces between neurons,
altering normal communication.
Scientists refer to the buildup of
amyloid beta in the brain as plaque

90

SCIENTIFIC KENYON

A neuron (green) affected with Alzheimer’s
disease has plaque buildup (red) along its
exterior.
Plaque by Adam Kaurman © Strittmatter Lab,
Yale University. Adapted by Ethan Bradley

formation, and these plaques can
be observed via brain imaging
and sampling of the fluid within
the brain called the cerebrospinal
fluid. Although a different type
of plaque, the damage done to
neurons by amyloid beta plaques
can be compared to the damage
done to teeth by cavity-causing
plaques. The second harmful
protein Alzheimer’s is responsible
for is phosphorylated tau. Normally,
tau is a protein that helps form the
branch-like structure of neurons.
Neurons reach in many directions
to connect with each other, and tau
is important for forming the fibrous
structure inside of the outstretched
arms of the neuron. In Alzheimer’s
disease, tau is altered so that these
fibrous structures become tangled,
hindering
neuronal
signaling.
These tangles are made up of a
form of tau called phosphorylated
tau, and doctors can see these on
brain images.
Alzheimer’s disease has no
known cure and very few effective
treatments. The most common
drug prescription for Alzheimer’s
disease is an Acetylcholinesterase
inhibitor, which makes it easier for
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signals to get from one neuron
to another1. When neurons are
signaling to each other, there are
proteins that surround the points
of contact between the neurons,
called synapses, to enhance the
transfer
of
neurotransmitters.
Acetylcholinesterase is one of these
proteins, and it clears the synapse
of
excess
neurotransmitters
by absorbing them back into
the
signal-sending
neuron.
Acetylcholinesterase
inhibitors
block acetylcholinesterase from
absorbing neurotransmitters from
the synapse, thereby allowing more
neurotransmitters to make it to the
receiving neuron.
However, acetylcholinesterase
inhibitors only modestly prolong
a person’s ability to use their
degrading brain to think and
remember. These drugs do not
reverse memory loss because
they do not directly prevent
amyloid beta or phosphorylated
tau buildup. This means that they
are not stopping the deterioration
of the brain. Sadly, mental health
disorders such as anxiety and
depression are common in people
with developing Alzheimer’s. The
most helpful treatment for this is
therapy, as many anti-depressant
drugs can worsen dementia and
confusion. To date, the outlook
for treatment is bleak for a person
being diagnosed with Alzheimer’s.
Because there are no known
cures for Alzheimer’s, scientists are
motivated to figure out the cellular
and molecular mechanisms of the
disease to find a target for potential
drugs. There are promising drug
discovery
studies
identifying
targetable pathways for alleviation
of the disease. As Alzheimer’s is a
disease that leads to cell death,
many of these therapeutic targets
are aiming to promote cellular
health in the locations that are
the most critical for cell survival
like energy production and excess
protein removal. Though normal

aging and Alzheimer’s progress
differently, many of the potential
treatments for Alzheimer’s, should
they prove to work in humans,
may be effective for the general
population. This is because these
drugs would enhance cellular
function regardless of a person’s
disease state. These neuronal
health-promoting qualities of the
potential treatments may have lifeelongating side effects for people
with and without Alzheimer’s.
Though speculative, this feature is
part of what makes research into
aging so exciting.

Pre-Clinical Health
Studies: Resveratrol
Going
back
to
my
grandmother’s love of red wine,
scientists have found that a
compound within the skin of red
grapes can clear the plaques and
tangles caused by Alzheimer’s in
the brains of mice. These mice
are born from parents that were
genetically altered by the scientists
to model familial Alzheimer’s, the
type of Alzheimer’s that can be
passed through generations. In this
way, these mice have Alzheimer’s
that develops along the time scale
of a mouse’s life. At seven months
old, they start to lose short term
memory abilities. After a year, the
mice perform horribly on memory
tasks. This mouse model also allows
scientists to study the cellular
components of Alzheimer’s because
the mice’s poor memory is due to
amyloid beta and phosphorylated
tau buildup, the same two factors
that are involved in humans2. Mice
models are the backbone of the
scientific knowledge of Alzheimer’s
because scientists can manipulate
their genes, environment, and diet
to match clinical treatments they
want to test, and can measure how
these factors affect their behavioral
and cellular health outcomes after
treatment.
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Resveratrol is found in many
different compounds: red grapes,
nuts, and berries, for example.
Comparatively, red wine has
a particularly high amount of
resveratrol because of how it is
produced. Resveratrol is found in
the skin of the grape, and a glass
of red wine has proportionally more
whole grapes than grape juice,
making wine the token dietary item
for resveratrol consumption. White
wine only uses the pulp of the
grape and contains no resveratrol.
However, when given to mice,
resveratrol is a supplement to their
diet via solid form so that scientists
can administer exact dosages. In
every study on dietary resveratrol,
the mice are given resveratrol for
many months, prior to the onset of
disease.
In a recent study, a group of
researchers from Barcelona treated
the mouse model of familial
Alzheimer’s with resveratrol for 10
months, starting at two months
of age. They tested the levels of
plaques and tangles within the
hippocampus of these resveratroltreated mice and compared these
results to the mice fed a normal diet
to determine how their brains had
been affected by the treatment. The
results showed that the diseased
mice treated with resveratrol had
the same number of plaques and
tangles as the healthy, untreated
mice. Through mechanistic work on
the cellular and molecular levels,
the scientists discovered that
resveratrol directly downregulates
the
cellular
pathways
that
synthesize the plaques and tangles
and upregulates the pathway that
breaks them down. For example,
resveratrol downregulated the
activity of a protein responsible
for generating amyloid beta
called BCAE1, upregulated the
activity of a protein responsible
for degrading amyloid beta called
neprilysin, and enhanced a proteinclearing pathway that prevents the

phosphorylation of tau. This result
showed that prolonged resveratrol
treatment is enough to clear the
plaques and tangles from the
hippocampus of diseased mice,
which is a critical finding, as many
other treatments for the disease fail
to have an effect on both plaques
and tangles3.
Alongside the finding that
resveratrol-treated
mice
had
healthier, younger-looking brains,
these
authors
showed
that
resveratrol treatment had a marked
effect on the mice’s memory. To
test this, they used a variety of
memory tests that have been
developed to determine what the
mice are thinking. The strongest
data for resveratrol came from
an object recognition test. Mice
have an ingrained preference for
new things; they love to explore.
Scientists can use this characteristic
to determine how well they
remember objects over some span
of time. In the first session, the mice
are shown two identical objects and
allowed to explore them. They will
smell and play with the objects until
the end of the session. Later, the
mice are given two objects again,
but one of them is replaced with a
new object. Because the mice like
new things, they will spend more
time playing with the new object if
they remember the old one. If they
spend about the same amount
of time with both objects, the
scientists conclude that the mouse
does not remember seeing one of
the objects before; it’s as if both
objects are new to the mouse.
In the resveratrol study, the
scientists did just this and found that
the untreated, diseased mice forgot
the object that they were given
after two hours, but the diseased
mice treated with resveratrol could
remember the object a day later3.
This was an exciting finding because
the mice’s ability to remember the
object after resveratrol treatment
overlapped, logically, the finding

that the resveratrol-treated mice
had healthier brains with less
plaques and tangles. Interestingly,
resveratrol has positive effects
on healthy aging mice as well.
In a separate study, a group of
scientists found that resveratrol
treatment strengthens neurons in
the hippocampus of these healthy
older mice, which lead to the
treated mice having better memory
than untreated mice4. Over and
over in the research on resveratrol,
scientists have shown that it has
beneficial effects on memory for
both healthy and Alzheimer’s mice.
The goal of all of these studies
in mice is to determine how
resveratrol affects the brain. The
question each study leaves us with
is simple: can wine do for humans
what resveratrol does for the mice?
My grandma would tell you yes, the
wine is helping her brain do what it
needs to. However, she is drinking
a fair amount of alcohol (safely,
of course), and her disease is still
progressing. If what is happening
in the mice is true for us, shouldn’t
her brain be getting better instead
of worse? It turns out, you need

According to studies done in mice, red wine can
promote brain function
Original image by Ethan Bradley
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Genetically modified Alzheimer’s mice perform better on memory tasks after prolonged treatment with resveratrol (a compound found in red wine)
“Wine” by TotoBaggins from Wikimedia (CC BY-SA 3.0), Original image by Ethan Bradley

more wine than anyone should
drink to get the dose of resveratrol
that the scientists are giving the
mice in the pre-clinical trials. In
a study published in the Journal
of Neuroscience, healthy older
adults were given resveratrol to
test if the drug could have the
predicted beneficial effect in
humans. Resveratrol increased
the connectivity of the adults’
hippocampi and thus improved
their memory. There was only
one issue: the participants were
given two hundred milligrams of
resveratrol per day5. For reference,
a glass of wine contains up to 2 mg
of resveratrol. So, in this resveratrol
pill, the participants were ingesting
the resveratrol-equivalent of 200
glasses of wine. Clearly, this pill is
much safer than asking someone to
drink 200 glasses of wine, but this
outlines a striking issue with wine
as an Alzheimer’s treatment: you
cannot drink enough wine to get
the full disease-preventing benefits
that we can see in mice. However,
drinking wine for the benefits of
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resveratrol may not be a lost cause.
To answer that question, we will
need to look into the research on
what happens to people who drink
wine, on a populational level, so that
we can understand if the benefits
of resveratrol hold up outside of a
clinical-controlled environment.

Does Drinking Wine
Prevent Dementia in
Humans?
The reason that it takes such
a high dose of resveratrol to make
a difference in the brain is due to
a structure that neuroscientists
call the blood brain barrier. The
brain gets nutrients and oxygen
from the blood to function, but
not everything in the bloodstream
makes it into the brain. There are
things floating in the bloodstream
that could be harmful to the brain:
bacteria, for example. To ensure
brain health, the body has a system
that connects the arteries in the
head to the brain with a selective

passing point between the two. In
this way, the brain is selective about
what is allowed across the blood
brain barrier. Resveratrol has a
hard time crossing the blood brain
barrier because, on a molecular
level, it’s larger than many of the
things that go through that passing
point. Therefore, humans have to
take a high dose to get enough
resveratrol into the brain to make a
difference.
Although buildup occurs over
time, it is feasible that drinking
a small amount of resveratrol
routinely for many years could
accumulate in the brain and have
positive effects. By this logic,
resveratrol would need to reach a
high enough concentration in the
brain to be effective. To test this
hypothesis, scientists compared
people who consume alcohol to
those who do not, at a populational
level. A 2017 study looked at the
relationship
between
alcohol
consumption (from any source: beer,
wine, whisky, etc.) and dementia.
If asked to predict the results of
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the study given no information on
resveratrol, one would imagine,
through experience or observation,
that drinking alcohol would have
negative effects on one’s ability
to remember things over time. It’s
true; too much alcohol in too short
of a time span can cause you to
‘black out,’ or have no memory
of what you did while under the
influence. However, after analyzing
data from over a hundred thousand
people, these scientists found that
people who drink modestly (6
drinks per week) had the lowest risk
of dementia, even after controlling
for age, sex, and education level6.
Hence, you can drink to remember,
if you drink a little bit every day for a
long time. Moreover, as expected,
these scientists found that wine
was the drink that best prevents
dementia.

Diet and Dementia:
You Are in the
Driver’s Seat!
So, this leaves us in a tricky
spot. Wine is good for us, to some
degree, but it is not going to
reliably prevent dementia. It only
reduces the risk by some small
factor. Is dementia worth worrying
about, or do we have too little
control over our future health? As
it turns out, choosing what you
want in your diet has a profound
effect on your mental and physical
health. In a study of older adults
in a retirement community around

Chicago, researchers found that
adherence to a newly developed
diet called the MIND diet reduced
the risk of Alzheimer’s disease by
more than half. Interestingly, the
MIND diet was more successful
in reducing dementia than the
famous
Mediterranean
diet.
Fittingly, the MIND diet is full of
items that are high in resveratrol
like wine, berries, and nuts7. The
best part of this diet is that it does
not ask participants to give up on
foods that are easy, like fried fast
food. It just asks you to limit the
rate of consumption of that type
of food to once per week. In this
way, diets such as the MIND diet
are likely to be helpful to people,
and this research can be used to
inform doctor’s recommendations
for diet. At the end of the day,
wine is not going to be a cureall for dementia and Alzheimer’s.
That being said, committing to
consistently putting good foods,
especially high-resveratrol foods,
into your body over a long time is
one of the clearest ways that we
can prevent dementia and keep
our minds healthy.
The real takeaway from
the preclinical mice research on
resveratrol is not that we should be
drinking as much wine as we can.
What the research tells us is that
the foods and drinks found in our
diet that have clear effects on the
brain. We can use the research to
our advantage and choose to put
things into our bodies that will
promote our health. Therefore,

since Alzheimer’s runs in my family,
I’m going to think through these
dietary recommendations when
I’m choosing what to eat and drink.
There’s no telling how things will
end up in the future, but choosing
healthy options is the best thing I
can do. If I am like the participants
in the MIND study, it will reduce
my risk of Alzheimer’s by more than
half.
There are no known successful
treatments for Alzheimer’s. Scientific
research is currently attempting to
uncover genetic causes of familial
Alzheimer’s, but my family does not
know what makes us so susceptible
to the disease. However, that does
not mean that the situation is
entirely out of control. We have the
ability to make behavioral decisions
that will mitigate how the genes
we inherit affect our lives. In the
preclinical mouse research, we’ve
seen that eating a diet that enables
our bodies to fight off diseases
like Alzheimer’s can promote our
brain’s function. We are not mice in
a super-controlled environment, so
the cellular effects of these choices
on the neurons in our brains are
harder to parse out. That being
said, we have more agency in how
we age than we may have initially
thought. Until a promising cure for
Alzheimer’s reaches the scientific
horizon, I’m going to support my
grandmother’s red wine drinking
habits and join her, on occasion.
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Hippocampus Alzheimer’s Patient
Red: Amyloid Beta Plaques; green: Neuro ibrillary Tangles;
Purple: Neuro ilament H; Blue: Dapi nuclear stain
By Danielle Beckman © MBF Bioscience
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